Initial clinical trials indicate that HDAC inhibitors from several structural classes are well tolerated and exhibit therapeutic activity against a variety of human malignancies, and the pleiotropic molecular mechanisms of action of these drugs are being uncovered.8, 9, 10 The elucidation of the key molecular targets of HDACi involved in glioma cell death is relevant for the development of more specific therapeutic strategies. Here, HDAC9 is linked to central nervous system cancer.